Nanoparticles submitted to the NCL may be subjected to testing for mycoplasma when
deemed necessary. Mycoplasma is a form of bacteria that lacks a nucleus and a cell wall, and are thus unaffected by many antibiotics. The types of nanoparticle formulations generally tested for mycoplasma contamination include those that in corporate a component derived from a bacterial culture, animal or hybridoma.
